thalidomide has been researched along with alpha-synuclein in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, S; Mante, M; Masliah, E; Rockenstein, E; Valera, E | 1 |
| Adame, A; Desplats, P; Fields, JA; Mante, M; Masliah, E; Rockenstein, E; Spencer, B; Trinh, I; Valera, E | 1 |
| Bernardini, R; Burgaletto, C; Cantarella, G; Carboni, E; Cardia, MC; Carta, AR; Casu, MA; Coroneo, V; De Simone, A; Ena, A; Etzi, M; Fusco, G; Greig, NH; Lai, F; Palmas, MF; Picci, L; Pisanu, A; Scerba, MT; Tweedie, D | 1 |
3 other study(ies) available for thalidomide and alpha-synuclein
| Article | Year |
|---|---|
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Cell Line, Transformed; Cytokines; Disease Models, Animal; Dopamine; Glial Fibrillary Acidic Protein; Immunologic Factors; Lenalidomide; Mental Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Parkinson Disease; RNA, Messenger; Signal Transduction; Thalidomide | 2015 |
Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Gliosis; Humans; Immunotherapy; Lenalidomide; Mice, Transgenic; Multiple System Atrophy; Proto-Oncogene Proteins c-akt; Signal Transduction; Single-Chain Antibodies; Thalidomide; Tumor Necrosis Factor-alpha | 2017 |
Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Cytokines; Disease Models, Animal; Disease Progression; Drug Repositioning; Humans; Microglia; Neuroprotective Agents; Parkinson Disease; Rats; Substantia Nigra; Thalidomide; Tumor Necrosis Factor-alpha | 2022 |